179 related articles for article (PubMed ID: 12008038)
1. Soluble interleukin-6 receptor enhanced by oncostatin M induces major changes in gene expression profile of human hepatoma cells.
Holub MC; Hegyesi H; Igaz P; Polgár A; Toth S; Falus A
Immunol Lett; 2002 Jun; 82(1-2):79-84. PubMed ID: 12008038
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells.
Cichy J; Rose-John S; Potempa J; Pryjma J; Travis J
J Immunol; 1997 Dec; 159(11):5648-53. PubMed ID: 9548508
[TBL] [Abstract][Full Text] [Related]
3. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130).
Geisterfer M; Richards CD; Gauldie J
Cytokine; 1995 Aug; 7(6):503-9. PubMed ID: 8580365
[TBL] [Abstract][Full Text] [Related]
4. Generation of 'truncated' interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R.
Holub MC; Szalai C; Polgár A; Tóth S; Falus A
Immunol Lett; 1999 May; 68(1):121-4. PubMed ID: 10397166
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes.
Paysant J; Blanqué R; Vasse M; Soria C; Soria J; Gardner CR
Cytokine; 2000 Jun; 12(6):774-9. PubMed ID: 10843763
[TBL] [Abstract][Full Text] [Related]
6. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
7. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes.
Gabay C; Silacci P; Genin B; Mentha G; Le Coultre C; Guerne PA
Eur J Immunol; 1995 Aug; 25(8):2378-83. PubMed ID: 7545121
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to rat soluble IL-6 receptor stimulate B9 hybridoma cell proliferation.
Thibault V; Richards CD; Botelho F; Gauldie J
FEBS Lett; 1997 May; 408(2):182-6. PubMed ID: 9187363
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatoma cell line and primary rat hepatocytes.
Igaz P; Tóth S; Rose-John S; Madurka I; Fejér G; Szalai C; Falus A
Cytokine; 1998 Aug; 10(8):620-6. PubMed ID: 9722935
[TBL] [Abstract][Full Text] [Related]
11. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown.
Rowan AD; Koshy PJ; Shingleton WD; Degnan BA; Heath JK; Vernallis AB; Spaull JR; Life PF; Hudson K; Cawston TE
Arthritis Rheum; 2001 Jul; 44(7):1620-32. PubMed ID: 11465713
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
15. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
16. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells.
Hurst SM; McLoughlin RM; Monslow J; Owens S; Morgan L; Fuller GM; Topley N; Jones SA
J Immunol; 2002 Nov; 169(9):5244-51. PubMed ID: 12391243
[TBL] [Abstract][Full Text] [Related]
17. Human T-cell leukemia virus type-I Tax induces expression of interleukin-6 receptor (IL-6R): Shedding of soluble IL-6R and activation of STAT3 signaling.
Horiuchi S; Yamamoto N; Dewan MZ; Takahashi Y; Yamashita A; Yoshida T; Nowell MA; Richards PJ; Jones SA; Yamamoto N
Int J Cancer; 2006 Aug; 119(4):823-30. PubMed ID: 16557588
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor.
Van Wagoner NJ; Oh JW; Repovic P; Benveniste EN
J Neurosci; 1999 Jul; 19(13):5236-44. PubMed ID: 10377335
[TBL] [Abstract][Full Text] [Related]
19. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.
Erices A; Conget P; Rojas C; Minguell JJ
Exp Cell Res; 2002 Oct; 280(1):24-32. PubMed ID: 12372336
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms.
McLoughlin RM; Hurst SM; Nowell MA; Harris DA; Horiuchi S; Morgan LW; Wilkinson TS; Yamamoto N; Topley N; Jones SA
J Immunol; 2004 May; 172(9):5676-83. PubMed ID: 15100312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
